Ian Herskowitz, MD
Endocrinology, Diabetes & Metabolism · Augusta, GANPI 1295880680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 989 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 8.4% — the pattern of someone who eats at a lot of different presentations.
Across 989 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$2K
- Sanofi-aventis U.S. LLC$1K
- Corcept Therapeutics$1K
- Amgen$1K
- Medtronic$1K
- plus $11K from 51 others
What the payments were for
- Speaking & faculty fees$1851%
- Food & beverage$18,63299%
- Education$620%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$422
- MINIMED 780G$364
- Minimed 670G System$237
- Kerendia$232
- Korlym$210
- AFREZZA$125
- NATPARA (PARATHYROID HORMONE)$125
- TEPEZZA$110
- TZIELD$109
- STEGLATRO$100
How this compares
$18,879 in reported general payments places this provider in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 378 | $497,537 |
| MounjaroTirzepatide | 150 | $212,094 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 108 | $113,420 |
| JardianceEmpagliflozin | 108 | $111,092 |
| FarxigaDapagliflozin Propanediol | 106 | $89,325 |
| TrulicityDulaglutide | 68 | $82,764 |
| Tresiba Flextouch U-100Insulin Degludec | 92 | $68,620 |
| ForteoTeriparatide | 13 | $52,184 |
| JanuviaSitagliptin Phosphate | 52 | $49,512 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 97 | $48,592 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $41,974 |
| SynthroidLevothyroxine Sodium | 389 | $34,460 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 24 | $32,631 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $30,403 |
| Humulin R U-500Insulin Regular, Human | 18 | $29,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,541 | $523,920457 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro | $1,584 | $365,496321 claims |
| Boehringer IngelheimJardiance, Synjardy | $884 | $118,451120 claims |
| AstraZenecaFarxiga | $763 | $89,325106 claims |
| MerckJanuvia | $427 | $49,51252 claims |
| AbbVieSynthroid | $641 | $34,460389 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,482 | $30,40447 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $189 | $13,5951,199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Augusta
- Leyla El-ChoufiAugusta$12K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.